Company Overview
Snapshot
Founded in June 2011 by Al Gabizon and Rami Kremien, LipoMedix operates with 1–10 employees. The company has secured $56K across one funding round. In January 2020, LipoMedix announced the publication of positive Phase 1 data for its lead product, Promitil, in a research journal.
Business overview
LipoMedix is a development-stage biopharmaceutical company focused on innovative cancer therapy through liposome delivery. The company's core product, Promitil, is designed to deliver chemotherapy with reduced toxicity while demonstrating strong antitumor effects. LipoMedix operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drug Delivery segments with its advanced therapeutics.
Strategic signal
In March 2019, LipoMedix initiated a Phase 1b trial (LIPORAD-2018) for Promitil in combination with radiotherapy for patients with advanced cancer. This development signals the company's progression in clinical validation and its commitment to exploring synergistic treatment approaches, which could significantly broaden the therapeutic potential of Promitil and attract further investment in oncology drug development.
Log in to access full profile ›Company Intelligence Q&A
- What is LipoMedix's primary therapeutic focus?
- LipoMedix focuses on developing innovative cancer therapies using liposome delivery systems, with its lead product, Promitil, designed to enhance antitumor effects while minimizing toxicity.
- When did LipoMedix announce the initiation of its Phase 1b trial for Promitil?
- In March 2019, LipoMedix announced the initiation of its Phase 1b trial (LIPORAD-2018) for Promitil in combination with radiotherapy for patients with advanced cancer.
- Has LipoMedix presented clinical data on Promitil at major conferences?
- In March 2019, LipoMedix presented new clinical data on Promitil at the American Association for Cancer Research (AACR) Annual Meeting 2019.
- When were positive Phase 1 data for Promitil published?
- In January 2020, LipoMedix announced the publication of positive Phase 1 data for Promitil (PL-MLP) in the research journal Investigational New Drugs.
- When did LipoMedix make changes to its Board of Directors?
- In August 2019, LipoMedix appointed new members to its Board of Directors and established a new Executive Committee.